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Inflammation and intimal hyperplasia associated
with experimental pulmonary embolism
Matthew J. Eagleton, MD, Peter K. Henke, MD, Catherine E. Luke, LVT, Angela E. Hawley, MS,
Asheesh Bedi, BS, Brian S. Knipp, MS, Thomas W. Wakefield, MD, and Lazar J. Greenfield, MD, Ann
Arbor, Mich
Objective: We tested the hypothesis that a venous thromboembolism to the pulmonary arterial system (pulmonary
embolism [PE]) would cause an inflammatory response within the pulmonary arterial (PA) wall marked by elevated
cytokines and chemokines and an influx of inflammatory cells.
Methods: Experimental PE was induced in 70 rats and confirmed with angiography and O2 saturation depression, and an
additional 70 rats underwent sham operations. PA and lung tissue were removed at 3 hours and at 1, 2, 4, 6, 8, and 14
days (n  10 per time point), were analyzed for proinflammatory cytokines and chemokines, and underwent histologic
analysis. Data were analyzed with analysis of variance and the unpaired Student t test.
Results: Average gross PE resolution was 40% at 2 days, 90% at 4 days, and 100% at 6 days. Only monocyte
chemoattractant protein–1 levels were greater in affected PAs compared with sham PAs at 3 hours, 1 day, and 2 days
(137 13 pg/mg protein, 285 40 pg/mg protein, and 249 36 pg/mg protein versus 101 6 pg/mg protein, 150
36 pg/mg protein, and 92  3 pg/mg protein; P < .01 for all). Keratinocyte-derived chemokine, tissue necrosis factor,
interleukin-10, nitric oxide, P-selectin, and E-selectin levels were not elevated. Neutrophils infiltrated the PA wall
beginning at 3 hours, peaked at 2 days (69.4  21.7 per five high-power fields; P < .01), and returned to baseline by 8
days after PE. Macrophages peaked at 1 day after PE (29.3  6.9; P < .01) and returned to baseline by 4 days after PE.
PE also was associated with a significantly increased intima to media ratio (P < .05), apparent at 4 days after PE and
persisting through 14 days.
Conclusion: PE is associated with an early influx of polymorphonuclears and macrophages and monocyte chemoattractant
protein–1 elevation within the PA wall. These are temporally associated with thrombus resolution and intimal
hyperplasia. These factors may mediate these two processes after PE. This offers targets for further study with the hopes
of minimizing the pathophysiologic response to PE. (J Vasc Surg 2002;36:581-8.)
Pulmonary embolism (PE) is a major health concern
with an estimated incidence rate of 69 cases per 100,000
and a prevalence rate of 3.5 cases per 1000 hospital admis-
sions.1,2 The acute sequelae of a PE can vary from no
symptomatology to sudden death. These outcomes and
subsequent resolution of pulmonary defects are influenced
by initial defect size, prior cardiopulmonary disease, and
patient gender.3 Resolution of pulmonary thromboemboli
occurs with endogenous thrombolysis, fragmentation, or
organization and recanalization. The latter process has
been associated with the development of intraluminal fi-
brous bands and intimal fibrosis and may contribute to the
development of PE-associated pulmonary hypertension.4,5
The morphology of a thromboembolus is similar to
that of a nondetached thrombus.6 Extensive research has
begun to document the process of thrombus resolution,
organization, and recanalization in deep venous thrombo-
sis (DVT). Thrombus development is associated with vein
wall inflammation marked by an early extravasation of
leukocytes and elevation in proinflammatory mediators and
selectins.7-11 Further thrombus organization involves neo-
vascularization, which can be augmented by interleukin-
8.12 Although the balance between plasminogen activators
and type I plasminogen activator inhibitors has been shown
to perhaps play a key role in the process of PE resolution,
the cellular and chemokine response in the PA wall or
parenchyma to an acute PE has not been evaluated.13 It is
unknown, however, whether the process is the same in a
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thrombus that develops in a vein (DVT) or in a thrombus
that develops in a vein and then lodges somewhere else,
such as the pulmonary circulation (PE).
The aim of this study was to test the hypothesis that the
pulmonary arterial (PA) wall would have an inflammatory
response to a PE associated with an elevation of inflamma-
tory cells and proinflammatory cytokines and chemokines.
In addition, we tested the hypothesis that PE is associated
with parenchymal inflammation and fibrosis.
MATERIALS AND METHODS
Animal model. Seventy Sprague-Dawley rats, weigh-
ing 300 to 350 g, were anesthetized with an inhalation
mixture of isoflurane (1% to 2%) and oxygen (100%) and
had inferior vena caval (IVC) thrombosis induced as previ-
ously described.7-12,14-17 Forty-eight hours later, the
thrombus within the IVC was massaged free and embolized
proximally. Through a vertical neck incision, the right
internal jugular vein was exposed and cannulated with
polyethylene tubing (PE-50, Becton Dickinson, Parsip-
pany, NJ). With fluoroscopic guidance (9400 X-ray Imag-
ing System, OEC-Diasonics, Salt Lake City, Utah), the
tubing was advanced into the right heart and a pulmonary
angiogram (Visipaque 320, Nycomed, Princeton, NJ; di-
luted 1:1 with normal saline solution) was performed to
verify and localize the PE. A maximum of 2 mL of contrast
was injected. A second group of 70 rats underwent sham
laparotomy with exposure of the IVC but no branch liga-
tion or clip placement. Forty-eight hours later, they under-
went a second sham operation followed by pulmonary
angiography as described previously.
Animals were killed at 3 hours and then at 1, 2, 4, 6, 8,
and 14 days after the PE. Ten animals were killed for each
group at each time point. Half of these animals (n  5 per
group per time point) had the affected portion of the PA
with some surrounding lung tissue dissected free, the
Fig 1. Photomicrographs show: A, sham animal (2 days after PE)
with few PA wall inflammatory cells and similar histologic appear-
ance to baseline; and B, experimental animal 2 days after PE with
increased neutrophil and macrophage cellular infiltrate into PA
wall and in surrounding lung parenchymal tissue. Hematoxylin
and eosin; original magnification, 60.
T, Thrombus; L, lumen; single arrow, neutrophil; double arrow,
macrophage.
Table I. Morphometric analysis (cells per five high-power fields) of inflammatory cells in PA wall indexed to time from PE
Baseline 3 Hours Day 1 Day 2
PE
Affected PA (n  6)
Total leukocytes 0.4  0.4 15.4  4.4*† 78.4  20.3*†‡ 96.0  29.9*†‡
Neutrophils 0 9.6  2.8*† 48.3  17.8*† 69.4  21.7*†‡
Macrophages 0.4  0.4 5.8  3.0 29.3  6.9*†‡ 26.6  10.9‡
Lymphocytes 0 0 0.8  0.6 0
Contralateral PA (n  6)
Total leukocytes 1.4  0.6 3.3  1.9 2.6  1.1 5.0  2.0
Neutrophils 1.0  0.6 1.3  1.3 0.8  0.6 3.5  1.3
Macrophages 0.4  0.4 1.5  0.6 1.8  1.1 1.5  0.9
Lymphocytes 0 0 0 0
Sham PA (n  6)
Total leukocytes 0.8  0.4 0.4  0.4 0.3  0.3 1.0  0.6
Neutrophils 0.4  0.2 0 0.25  0.25 0.4  0.4
Macrophages 0 0 0 0
Lymphocytes 0.4  0.4 0.4  0.2 0 0.6  0.4
*P  .01 compared with sham PA.
†P  .01 compared with contralateral PA.
‡P  .01 compared with baseline.
ANOVA, Analysis of variance; NS, not significant.
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thrombus removed, and the tissue washed three times in 5
mL of phosphate buffered saline solution, snap frozen in
liquid nitrogen, and stored at 70° C for future protein
analysis. Sections of lung parenchyma distal to the site of PE
were processed in a similar fashion. Sections of PA and
distal lung parenchyma were taken from the sham animals
and from the contralateral lung in the experimental group.
The other half of these animals (n  5 per group per time
point) underwent PA and tracheal perfusion fixation with
10% buffered formalin phosphate (Fisher Scientific, Pitts-
burgh, Pa). The affected, contralateral, and sham PA and
lung were removed and placed in 10% buffered formalin for
24 hours, followed by reagent alcohol 70% volume/vol-
ume (Labchem Inc, Pittsburgh, Pa) for subsequent perma-
nent section processing. Ten animals were killed without
any intervention for baseline controls, five for protein anal-
ysis and five for histologic analysis.
Oxygen saturation analysis. For assessment of the
physiologic response to the induced PE, arterial oxygen
saturation was measured. Before PE, immediately after PE,
and before death, sedated rats breathing room air under-
went dorsal tail arterial puncture. O2 saturations then were
measured on an OSM3 Hemoximeter (Radiometer Medi-
cal A/S, Denmark).
Cytokine and chemokine analysis and collagen as-
say. Specific cytokines and chemokines for study were
chosen on the basis of their documented importance in vein
wall inflammation after DVT formation.7,9,10-12,17,18 The
PA tissue and distal lung parenchyma were thawed, placed
in complete lysis buffer (Boehringer Mannheim, Indianap-
olis, Ind), homogenized for 45 seconds with a hand-held
homogenizer (TH, Omni International, Warrenton, Va),
and sonicated for 30 seconds (Micro Ultrasonic Cell Dis-
rupter, Kontes, Vineland, NJ). The homogenate was cen-
trifuged at 10,000 g for 5 minutes, and the supernatant and
sediment fractions separated. Measured levels of inflamma-
tory mediators were normalized to total protein in the
sample. Total protein quantitation was determined with a
bicinchoninic acid protein assay (Pierce, Rockford, Ill) with
serial dilutions of bovine serum albumin (Sigma Chemical,
St Louis, Mo) as standards. Analyses of inflammatory me-
diators, tissue necrosis factor- (TNF-), interleukin-10,
monocyte chemoattractant protein–1 (MCP-1), and tissue
growth factor– (TGF-) were performed with commer-
cially available, rat-specific, enzyme-linked immunosorbent
assays (ELISA; Endogen, Woburn, Mass) with sensitivities
of more than 10 pg/mL, more than 3 pg/mL, and more
than 5 pg/mL, respectively. A standard colorimetric kit
(Cayman Chemical, Ann Arbor, Mich) was used to measure
total nitric oxide. P-selectin, E-selectin, and keratinocyte-
derived chemokine (KC/GRO) were quantified in the
tissue homogenate with a direct ELISA method as previ-
ously described.17 The sensitivity was 0.5 ng/mL or more,
and negligible background was found when testing the
secondary antibody against the adsorbed antigens. Hy-
droxyproline levels in the lung parenchyma were deter-
mined with an acid hydrolysis colorimetric assay as previ-
ously described.12 Hydroxyproline standards ranged from
0 to 100 	g/mL.
Histopathology analysis and immunohistochemical
staining. Leukocyte extravasation into the PA wall was
assessed as previously described.7,9,17 Leukocyte morpho-
metric analysis was performed in a blinded fashion on
hematoxylin and eosin stained sections. Each rat had three
sections reviewed, and the section with the most complete
circumference was chosen. Five high-powered fields
(100) radially around the PA were assessed for neutro-
phils, monocytes, and lymphocytes on the basis of standard
morphologic criteria, including nuclear size, cytoplasmic
content, and cell size. Analysis began at the thrombus-vein
wall interface and extended the width of one high-power
field or up to, but not including, the lung parenchyma,
Day 4 Day 6 Day 8 Day 14 ANOVA
45.3  15.8*† 11.5  4.1* 1  0.6 1.5  1.5 P  .01
34.5  10.4*† 9.0  3.9 0 1.2  1.2 P  .01
10.8  6.8 2.0  1.7 1.0  0.6 0 P  .01
0 0.5  0.5 0 0 NS
3.0  2.0 1.7  0.9 0 NS
2.0  1.7 1.0  0.4 0 NS
0.8  0.3 0 0 NS
0.25  0.25 0.75  0.5 0 NS
0.6  0.6 0 0.25  0.25 NS
0.2  0.2 0 0.25  0.25 NS
0 0 0 NS
0.4  0.4 0 0 NS
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whichever was smaller. On samples with no thrombus,
analysis began at the endothelial cell layer of the PA. In
addition, morphometric analysis was performed on the
lung parenchyma distal to the affected PA. Again, five
high-powered fields in the distal segment underwent
counts for neutrophils, monocytes, and lymphocytes as
described previously. Morphometrics were confirmed by
comparison with neutrophils and macrophages stained
with rat anti-polymorphonuclears (PMNs) and ED-1 anti-
body, respectively, as previously described.9
Brillmeyer’s trichrome stain was applied to paraffin
embedded tissue to assess collagen distribution. After the
sections were deparaffinized, they were placed in hematox-
ylin for 40 seconds, followed by 0.2% (weight/volume)
acid fuchsin for 1 minute. This was followed by a 3-hour
incubation at room temperature in 0.5% anilin blue, 2%
Orange G, and 1% phosphomolybdic acid and a subsequent
dehydration in 100% ethanol. All reagents were from Sigma
Chemical.
Intimal hyperplasia was estimated with measurements
made, in a blinded fashion, from the luminal surface to the
internal and external elastic laminae at three separate, ran-
domly selected locations along each PA and then aver-
aged.19 Digitized images were analyzed with Adobe Pho-
toshop 5.0 (Adobe Systems Incorporated, San Jose, Calif).
Statistical evaluation and animal use. Statistical
evaluation included mean  standard error of the mean,
analysis of variance, Bonferroni post hoc analysis, and un-
paired Student t tests. All animals used in this study were
housed and cared for in the University of Michigan Unit for
Laboratory Animal Medicine under the direction of a vet-
erinarian according to the Principles of Laboratory Animal
Care (National Society for Medical Research) and Guide
for the Care and Use of Laboratory Animals (National In-
stitutes of Health Publication No. 86-23, revised 1985).
RESULTS
Animal model.20 Induction of PE was attempted in
87 animals, with 70 animals (80.4%) obtaining PE visible
on pulmonary angiogram. Of the animals that did not show
a PE, five died at surgery, one did not have an IVC
thrombus develop, and 11 had no PEs visible on angiogra-
phy. Of the 1 animals with no angiographically visible PE,
six had no thrombus found at necropsy and five had a large
thrombus retained in the right ventricle of the heart. PE
distribution with angiography was: 72% to the right caudal
lobar PA, 8.5% to the right cranial lobar PA, 2.9% to the
right medial lobar PA, 7% to the main right PA, and 8.5% to
a branch of the left PA.
Arterial O2 saturations were similar between experi-
mental and sham animals at baseline (96.5%  0.4% versus
97.3%  0.3%, respectively). After PE, experimental ani-
mals had lower O2 saturations compared with sham animals
(87.7% 1.5% versus 96.4% 0.4%, respectively; P .01).
This reduction in O2 saturation resolved by 1 day after PE.
Thrombus within the PA was visible at death at the
early time points. At all time points with thrombus present,
thrombus was not adhered to the PA wall. Mean thrombus
resolution after PE (determined at death by the absence of
thrombus in the PA) was 40% at 2 days, 90% at 4 days, and
100% at 6 days. In one instance, thrombus not visualized
with angiography was found within the PA of the contralat-
eral lung at the 3-hour time point. No PA thrombus was
found in any of the sham animals.
Histologic evaluation and morphometric analysis
of pulmonary artery after pulmonary embolism. At
baseline, almost no inflammatory cells were present in the
PA wall (Table I). Similarly, at each time point, few inflam-
matory cells were within the PA wall in sham animals (Fig 1,
A), and no differences were seen from baseline in histologic
appearance or morphometric analysis. At 3 hours after PE,
evidence was found of inflammatory cell infiltration within
the outer margin of the PA wall. Compared with sham
animals, there was a 38-fold increase in leukocytes (P 
.01), with a differential of 62% 18% neutrophils (P .01)
and 38% 19% macrophages. At scattered points along the
embolus, neutrophils lined the outer edge. By 1 and 2 days
after PE, there was increased neutrophil and macrophage
infiltration into the PA wall (Fig 1 , B) and evidence of
PMNs within the PA wall vasovasorum. At 2 days after PE,
total leukocyte count increased 320-fold compared with
sham animals (P .01), with 72% 22% neutrophils (P
.01) and 28% 11% macrophages. At 4 days after PE, most
thrombi had lysed and a concurrent decrease in inflamma-
tory cell infiltrate was observed. Total leukocyte count
dropped to a 45-fold (P .01) increase over sham animals,
with 77% 21% neutrophils (P .01). At 14 days after PE,
the PA wall appeared similar to baseline with no significant
difference in leukocyte count. On examination of the con-
tralateral PA at all time points, no histologic or morpho-
metric differences were seen compared with sham animals
or with baseline.
Evaluation of the PA intima and media revealed a
change over time as well. Starting at 4 days after PE, there
was an increase in intimal thickness. This was associated
with increased cellularity of the intimal layer as compared
with sham animals (Fig 2, A and B). The intimal hypercel-
lularity persisted through 14 days after PE. Although the
identity of these cells is not clear, they do not stain with
PMN or macrophage-specific markers and likely represent
proliferating smooth muscle cells. In addition, at both time
points, the medial smooth muscle cells developed more
rounded nuclei and cellular structure and appeared to have
more evidence of mitoses. Trichrome staining allowed PA
intimal and medial thickness to be quantified. Two-day,
4-day, 6-day, and 14-day time points were evaluated. Com-
pared with sham animals, there was a significant increase in
the intima to media ratio apparent at 4 days (0.23 versus
0.12; P .01), 6 days (0.23 versus 0.11; P .05), and 14
days (0.27 versus 0.14; P  .05; Fig 2 , C).
Histologic evaluation and morphometric analysis
of lung parenchyma after pulmonary embolism. Mor-
phometric analysis was performed on distal lung segments
at baseline and after PE at time points 3 hours and 1, 2, 4,
and 14 days. At baseline, there were predominantly macro-
phages within the lung parenchyma, with few neutrophils
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(Table II). After PE, there was a significant increase in the
number of macrophages present compared with sham ani-
mals (Table II). This difference was first present at 3 hours
and persisted through 4 days after PE. Unlike the PA wall,
the number of neutrophils did not significantly increase at
any of the time points. A similar inflammatory response was
present in the distal lung segment from the contralateral
lung, with significant elevations in total leukocytes and
macrophages at 2 and 4 days (P  .01; Table II).
Cytokine and chemokine levels within the pulmo-
nary arterial wall after pulmonary embolism.20 Cyto-
kines and chemokines in the PA wall, after PE, were quan-
tified with ELISA. KC/GRO, interleukin-10, TNF-, and
nitric oxide levels did not differ significantly among the
groups, and P-selectin and E-selectin levels were not de-
tectable in the PA wall. KC/GRO and interleukin-10 levels
were significantly elevated in affected PAs, contralateral
PAs, and sham PAs compared with baseline controls. Only
MCP-1 levels from the affected PA wall were elevated
compared with the sham PAs (Fig 3), and this elevation
occurred at 2 days after PE. MCP-1 levels also were signif-
icantly increased from baseline (115  30 pg/mg protein)
at day 1 after PE (285 40 pg/mg protein; P .01) in the
affected PA from the experimental group (Fig 3) and the
Fig 2. Photomicrographs show: A, intimal hyperplasia in PA wall 4 days after PE; and B, no intimal hyperplasia in
sham animals at 4 days after PE. Trichrome stain; original magnification, 100. C, Graphic representation of intima to
media ratio from experimental and sham animals.
*P  .05.
***P  .01.
L, Lumen; solid arrow, internal elastic lamina.
Table II. Morphometric analysis (cells per five high-power fields) of inflammatory cells in distal lung parenchyma
indexed to time from PE
Baseline 3 Hours Day 1 Day 2 Day 4 Day 14 ANOVA
PE
Affected lung (n  6)
Total leukocytes 50.6  3.8 97.0  8.4† 65.0  8.3 76.6  2.9* 75.4  5.0* 66.5  6.8 P  .01
Neutrophils 7.2  1.3 11.2  1.5 5.6  1.6 8.6  1.4 10.6  1.5 11.2  1.6 NS
Macrophages 43.4  2.6 85.8  9.2*† 59.4  8.0* 68.0  3.6* 64.8  5.3* 55.4  5.3 P  .01
Contralateral lung (n  6)
Total leukocytes 79.2  7.5 81.4  13.3* 84.0  5.1* 92.2  3.4*† 71.6  4.6† P  .01
Neutrophils 27.8  9.5 8.0  2.8 14.6  4.0 8.6  1.5 16.0  2.3 NS
Macrophages 51.4  5.1* 73.4  11.2*† 69.4  3.3*† 83.6  3.8*† 55.6  2.7 P  .01
Sham lung (n  6)
Total leukocytes 70.2  6.0 37.0  5.6 49.4  4.3 53.6  5.7 54.6  4.1 P  .01
Neutrophils 24.0  4.7 13.0  1.6† 17.2  2.6 12.8  1 12.6  3.2 P  .01
Macrophages 46.2  3.9 24.0  4.7† 32.2  2.5 40.8  5.5 42.0  2.3 P  .01
*P  .01 compared with sham PA.
†P  .01 compared with baseline.
ANOVA, Analysis of variance; NS, not significant.
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contralateral PA (311  70 pg/mg protein; P  .01). At
no time did MCP-1 levels from sham PAs increase over
baseline.
Collagen and inflammatory chemokine and cyto-
kine levels within the lung parenchyma after pulmonary
embolism. MCP-1, hydroxyproline, and TGF- levels
were measured in lung tissue at baseline and at 3 hours and
1, 2, 4, and 14 days after PE. There were no significant
differences in the MCP-1 levels among affected lungs,
contralateral lungs, and sham lungs. There was a trend,
however, toward elevated MCP-1 levels at 1 and 2 days
after PE, mirroring the results seen in the PA wall (P .12
and P .4). Hydroxyproline was not significantly different
among the groups nor compared with baseline. TGF-was
suppressed in both lungs of experimental animals compared
with shams at 3 hours after PE (152  18 pg/mg protein
and 128  38 pg/mg protein versus 383  87 pg/mg
protein; P  .01) but had no difference at any other time
point.
DISCUSSION
For examination of the inflammatory effect of PE on
the PA wall and parenchyma, a reproducible model of PE
was developed in a small animal. The strengths of this
model are that the PE more closely resembles the clinical
disease, with an in situ thromboembolus traveling into the
pulmonary circulation. This differs from most previously
reported studies in which exogenous thrombus or other
material are injected into the venous or PA circulation.21,22
This model is reproducible with an 80.4% success rate,
which is similar to models in which exogenous clot was
introduced into the venous circulation.22 Other benefits of
this model are that it allows for accurate radiographic
localization of the PE within specific PA segments. Finally,
the PE’s physiologic effect was marked by transient hypoxia
with subsequent resolution, not unlike the situation in
humans. No other small animal models have documented
this physiologic response. There was, however, variability in
the timing of thrombus resolution, which may reflect vari-
ability in the size of the thrombus. No correlation could be
made between the time of thrombus resolution and corre-
sponding cytokine and chemokine levels or degree of in-
flammatory cell infiltration. In addition, no evidence was
seen of pulmonary infarction. This is likely the result of
sufficient collateral blood supply to the affected lung tissue
provided by other PA branches or bronchial arteries.
Mechanisms that may account for the physiologic man-
ifestations of PE also were suggested by this study. PE is
associated with a leukocyte influx, not only in the PA wall
but also the parenchyma. This influx of leukocytes occurs
early after PE (1 day). In the PA wall, the inflammatory cell
population is predominately neutrophils but with a con-
comitant rise in macrophages. In the parenchyma, the
inflammatory cell response is predominantly that of macro-
phages. Temporally, this rise in PA wall neutrophils corre-
lates with the cellular inflammatory response seen in the
DVT model.7,8 The early rise in the macrophage cell line,
however, is different. In the animal models of DVT, the
macrophages infiltrate the vein wall, becoming the pre-
dominate leukocyte at approximately day 3 after thrombus
formation.7 The timing of the influx of macrophages within
the PA wall does correlate with that in the vein wall after
DVT if the frame of reference is from the time of clot
formation. This suggests that the thromboembolus may
direct PA wall and parenchymal cellular events and not
primarily the PA.
Fig 3. Graphic representation of MCP-1 levels (pg/mg protein) over time from affected and contralateral PA wall in
experimental (PE) animals and from PA wall of sham animals.
*P  .01 compared with sham.
‡P  .01 compared with baseline.
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Of all of the chemokines and cytokines assessed after
PE, only MCP-1 was elevated within the PA wall in exper-
imental animals compared with sham animals. This eleva-
tion peaked at 2 days after PE and preceded the peak of
macrophage influx. This differs from the response reported
after development of thrombus in the IVC. Within the IVC
wall, epithelial neutrophil activating protein–78, TNF-,
interleukin-6, MCP-1, macrophage inflammatory pro-
tein–1, and P-selectins all rise.7,18 Interestingly, P-selectin
was not detected in the PA wall after PE. This is distinctly
different from DVT genesis in which P-selectin is important
in mediating leukocyte interaction with endothelial cells,
other leukocytes, and platelets.23,24 In DVT models, block-
ade of P-selectin has been found to decrease associated
perithrombotic inflammation and thrombosis propagation
but not leukocyte vein wall influx.9-11 Its inhibition or
deletion, however, does not completely prevent inflamma-
tory cell infiltration into the vessel wall, which likely relies
on several different cellular adhesion molecules. Further-
more, the inflammatory cells in the PA wall after PE may
originate from the lung parenchyma and rely on a com-
pletely different mechanism of infiltration. The lack of
selectin elevation in the PA wall after PE suggests that the
selectins may have little role in promoting inflammatory cell
extravasation but may be more important in the thrombo-
genesis.
MCP-1 and monocyte/macrophages likely play an im-
portant role in embolism resolution. MCP-1 is a chemoat-
tractant and activator of monocytes and can be produced by
a variety of cell types within a resolving thrombus.25-27
Monocytes, the precursors of tissue macrophages, produce
tissue plasminogen activator and urokinase.28,29 Mono-
cytes, however, also produce inhibitors of fibrinolysis,
whose procoagulant activity may be mediated by P-selectin,
which is not elevated in this model.30-32 There is an accu-
mulation of macrophages that occurs within both the PA
wall and the parenchyma after PE and corresponds to the
MCP-1 PA wall kinetics. This rise is temporally associated
with thrombus resolution. MCP-1 may shift the macro-
phage function towards fibrinolysis. Humphries and col-
leagues33 have shown that after thrombus formation in rats,
MCP-1 levels increase in blood, thrombi, and adjacent
vessel wall. In addition, injection of MCP-1 into newly
formed thrombus increased organization and resolution of
the thromubs.33 In this model, the mechanism of action
may be through recruitment of macrophages to the site of
embolism or through the differentiation of these cells into
macrophages secreting more fibrinolytic proteins than in-
hibitors to allow PE resolution.
Other inflammatory mediators likely play a role in the
PA wall inflammatory response, but none were detected in
this model. The elevation of KC/GRO and interleukin-10
in both sham and experimental animals compared with
baseline controls suggests that there was a systemic inflam-
matory response that is likely attributable to the operations
and the angiography. Other inflammatory mediators may
have been overshadowed because of this response. The
importance of MCP-1 in this model is further strength-
ened, however, because it was not elevated in sham animals
compared with baseline controls and thus its elevation in
experimental animals can be attributed to the PE.
MCP-1 and the macrophage cell line also may play an
important role in the development of intimal hyperplasia
observed after PE. The PA intimal region becomes thick-
ened and hypercellular in this PE model shortly after the
peak elevations of MCP-1 and macrophages. Experimental
evidence suggests that MCP-1 may play an important role
in the development of intimal hyperplasia. In models with
vein grafts, the development of intimal hyperplasia is asso-
ciated with the presence of monocytes and macrophages
and the upregulation of MCP-1 gene expression.34 Deple-
tion of macrophages in a rat model of vein graft intimal
hyperplasia leads to suppression of intimal hyperplasia with
resumption of the process as macrophages return.35 Tria-
zolopyrimidine has been shown to attenuate intimal hyper-
plasia in a balloon injury model.36 This occurs by reducing
MCP-1 expression and inhibiting arterial wall macrophage
accumulation. Finally, after carotid artery injury in rats,
intimal hyperplasia is inhibited by treatment with an anti–
MCP-1 antibody.37 Treatment with recombinant MCP-1,
however, did not promote intimal hyperplasia. Further
work is necessary to evaluate the development of intimal
hyperplasia in the PA wall after a PE and to further define
the role of MCP-1 and macrophages in this process and the
overall process of pulmonary inflammation.
No evidence was found of significant pulmonary paren-
chymal fibrosis after one major PE. This is supported by the
lack of qualitative differences in the collagen staining
among the groups and by no differences in the levels of
parenchymal hydroxyproline. TGF- has been shown to be
a regulator of pulmonary fibrosis after lung injury.38,39
After one PE, despite a local and regional inflammatory
response, TGF- levels were initially suppressed before
returning to levels equivalent to sham animals. Although
TGF- has been important in mediating acute lung injury,
its role in mediating lung injury after PE is less clear.40
Thus, in this animal model of single large PE, parenchymal
fibrosis does not occur, but persistence of PA fibrosis does
(at least through 14 days). Given the physiologic relevance
of this model, further experiments will determine how PA
injury can be attenuated and how best to apply these
therapies clinically.
REFERENCES
1. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM,
Melton LJ III. Trends in the incidence of deep vein thrombosis and
pulmonary embolism. Arch Intern Med 1998;158:585-93.
2. Proctor MC, Greenfield LJ. Pulmonary embolism: diagnosis, incidence
and implications. Cardiovasc Surg 1997;5:77-81.
3. Menendez R, Nauffal D, Cremades MJ. Prognostic factors in restora-
tion of pulmonary flow after submassive pulmonary embolism: a multi-
ple regression analysis. Eur Respir J 1998;11:560-4.
4. Morrell MT, Dunnill MS. Fibrous band in conducting pulmonary
arteries. J Clin Pathol 1967;20:139-44.
5. Moser KM, Auger WR, Fedullo PF. Chronic major-vessel thromboem-
bolic pulmonary hypertension. Circulation 1990;81:1735-43.
6. Wagenvoort CA. Pathology of pulmonary thromboembolism. Chest
1995;107:10S-7S.
JOURNAL OF VASCULAR SURGERY
Volume 36, Number 3 Eagleton et al 587
7. Wakefield TW, Strieter RM, Wilke CA, Kadell AM, Wrobleski SK,
Burdick MD, et al. Venous thrombosis-associated inflammation and
attenuation with neutralizing antibodies to cytokines and adhesion
molecules. Arterioscler Thromb Vasc Biol 1995;15:258-68.
8. Downing LJ, Strieter RM, Kadell AM, Wilke CA, Brown SL, Wrobleski
SK, et al. Neutrophils are the initial cell type identified in deep venous
thrombosis induced vein wall inflammation. ASAIO J 1996;42:M677-
82.
9. Wakefield TW, Strieter RM, Downing LJ, Kadell AM, Wilke CA,
Burdick MD, et al. P-selectin and TNF inhibition reduce venous throm-
bosis inflammation. J Surg Res 1996;64:26-31.
10. Downing LJ, Wakefield TW, Strieter RM, Prince MR, Londy FJ,
Fowlkes JB, et al. Anti-P-selectin antibody decreases inflammation and
thrombus formation in venous thrombosis. J Vasc Surg 1997;25:816-
28.
11. Eppihimer MJ, Schaub RG. P-selectin-dependent inhibition of throm-
bosis during venous stasis. Arterioscler Thromb Vasc Biol 2000;20:
2483-8.
12. Henke PK, Wakefield TW, Kadell AM, Linn MJ, Varma MR, Sarkar M,
et al. Interleukin-8 administration enhances venous thrombosis resolu-
tion in a rat model. J Surg Res 2001;99:84-91.
13. Lang IM, Moser KM, Schleef RR. Elevated expression of urokinase-like
plasminogen activator and plasminogen activator inhibitor type 1 dur-
ing the vascular remodeling associated with pulmonary thromboembo-
lism. Arterioscler Thromb Vasc Biol 1998;18:808-15.
14. Reyers I, Mussoni L, Donati MB, de Gaetano G. Failure of aspirin at
different doses to modify experimental thrombosis in rats. Thromb Res
1980;18:669-74.
15. Millet J, Thevaniaux J, Pascal M. A new experimental model of venous
thrombosis in rats involving partial stasis and slight endothelial alter-
ations. Thromb Res 1987;45:123-33.
16. Monreal M, Silveira P, Monreal L, Monasterio J, Angles AM, Lafoz E,
et al. Comparative study on the anti-thrombotic efficacy of four low-
molecular-weight heparins in three different models of experimental
venous thrombosis. Haemostasis 1991;21:91-7.
17. Henke PK, DeBrunye LA, Strieter RM, Bromberg JS, Prince M, Kadell
AM, et al. Viral IL-10 gene transfer decreases inflammation and cell
adhesion molecule expression in a rat model of venous thrombosis.
J Immunol 2000;164:2131-41.
18. Myers D, Farris D, Hawley A, Wrobleski S, Chapman A, Stoolman L, et
al. Selectins and interleukin-10 influence acute thrombus formation in a
mouse model of venous thrombosis. J Surg Res. In press 2002.
19. Sarac TP, Riggs PN, Williams JP, Feins RH, Baggs R, Rubin P, et al.
The effects of low-dose radiation on neointimal hyperplasia. J Vasc Surg
1995;22:17-24.
20. Eagleton MJ, Henke PK, Luke CE, Wakefield TW, Greenfield LJ.
Pulmonary embolism is associated with increased pulmonary arterial
wall MCP-1 levels. Surg Forum 2001;LII:342-3.
21. Clozel JP, Holvoet P, Tschopp T. Experimental pulmonary embolus in
the rat: a new in vivo model to test thrombolytic drugs. J Cardiovasc
Pharmacol 1988;12:520-5.
22. Stassen JM, Lijnen HR, Kieckens L, Collen D. Small animal thrombosis
models for the evaluation of thrombolytic agents. Circulation 1991;83:
IV65-72.
23. Walchek B, Moore KL, McEver RP, Kishimoto TK. Neutrophil-neu-
trophil interactions under hemodynamic shear stress involve L-selectin
and PSGL-1. A mechanism that amplifies intitial leukocyte leukocyte
accumulation of P-selectin in vitro. J Clin Invest 1996;98:1081-7.
24. Konstantopoulos K, Neelamegham S, Burns AR, Hentzen E, Konsas
GS, Snapp KR, et al. Venous levels of shear support neutrophil-platelet
adhesion and neutrophil aggregation in blood via P-selectin and 2-
integrin. Circulation 1998;98:873-82.
25. Ajuebor MN, Flower RJ, Hannon R, Christir M, Bowers K, Verity A, et
al. Endogenous monocyte chemoattractant protein-1 recruits mono-
cytes in the zymosan perinotitis model. J Leukoc Biol 1998;63:108-16.
26. Conti P, Pang X, Boucher W, Letourneau R, Reale M, Barbacane RC,
et al. Monocyte chemotactic protein-1 is a proinflmamatory cytokine in
rat skin injection sites and chemoattracts basophilic granuylar cell. Int
Immunol 1997;9:1563-70.
27. Colotta F, Sciacca FL, Sironi M, Luini W, Raviet MJ, Mantovbani A.
Expression of monocyte chemotactic protein-1 by monocytes and
endothelial cells exposed to thrombin. Am J Pathol 1994;144:975-85.
28. Lundgren CH, Sawa H, Soble BE, Fujii S. Modulation of expression of
monocyte/macrophage plasminogen activator activity and its implica-
tion for attenuation of vasculopathy. Circulation 1994;90:1927-34.
29. Kung SKP, Lau HKF. Modulation of the plasminogen activation system
in murine macrophages. Biochim Biophys Acta 1993;1176:113-22.
30. Castellote JC, Grau E, Linde MA, Pujol-Marx N, Rutllant ML. Detec-
tion of both type-1 and type-2 plasminogen activator inhibitors in
human monocytes. Thromb Haemost 1990;63:67-71.
31. Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of
expression and function of tissue factor. Thromb Haemost 1991;66:67-
79.
32. Burnand KG, Gaffney PJ, McGuinness CL, Hjmphries J, Quarmby JW,
Smith A. The role of the monocyte in the generation and dissolution of
arterial and venous thrombi. Cardiovasc Surg 1998;6:119-25.
33. Humphries J, McGuinness CL, Smith A, Waltham M, Poston R,
Burnand K. Monocyte chemotactic protein-1 (MCP-1) accelerates the
organization and resolution of venous thrombi. J Vasc Surg 1999;30:
894-900.
34. Stark VK, Hoch JR, Warner TF, Hullett DA. Monocyte chemotactic
protein-1 expression is associated with the development of vein graft
intimal hyperplasia. Arterioscler Thromb Vasc Biol 1997;17:1614-21.
35. Hoch JR, Stark VK, van Rooijen N, Kim JL, Nutt MP, Warner TF.
Macrophage depletion alter vein graft intimal hyperplasia. Surgery
1999;126:428-37.
36. Poon M, Cohen J, Siddiqui Z, Fallon JT, Taubman MB. Trapidil
inhibits monocyte chemoattractant protein-1 and macrophage accumu-
lation after balloon arterial injury in rabbits. Lab Invest 1999;79:1369-
75.
37. Furukawa Y, Matsumori A, Ohashi N, Shioi T, Ono K, Harada A, et al.
Anti-monocyte chemoattractant protein-1/monocyte chemotactic and
activating factor antibody inhibits neointimal hyperplasia in injured rat
carotid arteries. Circ Res 1999;84:306-14.
38. Phan S, Gharaee-Kermani M, Wolber F, Ryan US. Stimulation of rat
endothelial cell tranforming growth factor-beta production by bleomy-
cin. J Clin Invest 1991;87:148-54.
39. Giri SN, Hyde DM, Hollinger MA. Effect of antibody to transforming
growth factor  on bleomycin-induced accumulation of lung collagen
in mice. Thorax 1993;38:959-66.
40. Pittet JF, Griffiths MJD, Geiser T, Kaminski N, Dalton SL, Huan X, et
al. TGF- is a critical mediator of acute lung injury. J Clin Invest
2001;107:1537-44.
Submitted Nov 8, 2001; accepted Feb 8, 2002.
JOURNAL OF VASCULAR SURGERY
September 2002588 Eagleton et al
